As of Oct 20
| -0.75 / -1.76%|
The 7 analysts offering 12-month price forecasts for Supernus Pharmaceuticals Inc have a median target of 49.00, with a high estimate of 61.00 and a low estimate of 41.00. The median estimate represents a +17.08% increase from the last price of 41.85.
The current consensus among 7 polled investment analysts is to Buy stock in Supernus Pharmaceuticals Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.